

## DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY

August 22, 2016 - Washington - Saluggia (VC) - DiaSorin Group (FTSE Italia Mid Cap: DIA), a multi-national corporation, based in Saluggia, Italy, working through its U.S. subsidiary, DiaSorin, Inc. in Stillwater, MN, is pleased to announce that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, for the development of new serological tests to detect Zika virus infections.

*"We are excited to have been given an opportunity to participate in this bid and leverage our 40 years of experience in infectious disease immunoassay product development and commercialization,"* said John Walter, President of DiaSorin, Inc. *"This strong tradition of infectious disease testing will enable DiaSorin to quickly deliver a product that will demonstrate real value to laboratories and help reduce the current burdensome testing load during this public health emergency."*

DiaSorin intends to present these new assays on the LIAISON<sup>®</sup> XL, which will offer laboratories a fully-automated solution for the detection of Zika virus infections.

ASPR/BARDA is seeking to advance several diagnostic tests for Zika to help improve their availability and potentially lead to lower costs for patients. The project will be funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO1002016000027C.

The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis, or red eyes. The illness usually is mild with symptoms lasting for several days to a week. People typically do not get sick enough to require hospitalization and they very rarely die of Zika. For this reason, many people might not realize they have been infected. However, Zika virus infection during pregnancy can cause a serious birth defect called microcephaly, as well as other severe fetal brain defects.

Tests will be produced at the Stillwater facility and are expected to be sold in the U.S. following FDA clearance. After the launch in the U.S. market, DiaSorin will assess timing to apply for further clearances to make its tests available in other markets, including Europe, Brazil, and China.

*"I am extremely proud that DiaSorin has reached another important milestone"* commented Carlo Rosa, CEO of DiaSorin Group. *"Being selected by BARDA among a panel of European and US companies, confirms once again our innovation ability within the diagnostic sector. DiaSorin's entry into the Zika test market enriches our already important panel of infectious disease tests, confirming the Group's technological excellence and competence in complex markets such as the U.S."*



The Diagnostic Specialist

---

## Press Release

### **About DiaSorin in the U.S.**

*DiaSorin operates in the North American market (which accounts for about 25% of the Group's turnover), with over 500 employees working in the two facilities and Research and Development centers in Stillwater and Cypress. Half of DiaSorin Group researchers work in the United States.*

### **About DiaSorin Group**

*Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD "diagnostics specialist".*

### **For additional information, please contact:**

Riccardo Fava  
Investor Relations & Corporate Communication Senior Director  
Tel: +39.0161.487988  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

Ines Di Terlizzi  
Investor Relator  
Tel: +39.0161.487567  
[ines.diterlizzi@diasorin.it](mailto:ines.diterlizzi@diasorin.it)